DEXWireNews

$ZYNE Plenty of time to get into Zynerba Pharma

NASDAQ:ZYNE   None
Don't worry that you missed out on this initial move in the price, still plenty of room to run for ZYNERBA PHARMA, which specializes in the development and commercialism of cannabis treatments for conditions ranging from Epilepsy and Osteoarthritis. Although the stock has had a considerable move this month, it is still a low cap company with huge potential, so maybe no need to rush in but it is a long term investment, with a small allocation of capital for us.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media
면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.